News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Deals and strategy
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
This article provides an earnings forecast for Texas Ventures Acquisition III Ord Shs Class A (TVA), focusing on future EPS and revenue growth estimates. It includes current stock information such as its market capitalization and P/E ratio, alongside a list of peer companies for …
This article provides a technical analysis of Texas Ventures Acquisition III Ord Shs Class A (TVA), detailing its support, resistance, indicators, and moving averages. It presents an overview of various technical indicators like MACD, RSI, and KDJ, alongside moving average data from MA5 to …
This article provides a financial analysis of Texas Ventures Acquisition III Ord Shs Class A (TVA), focusing on its profitability and balance sheet. It includes real-time stock quotes, market capitalization, and P/E ratio, along with an overview of the company's financial data and discussions. …
This article provides a detailed company profile for Texas Ventures Acquisition III Ord Shs Class A (TVA). It includes current trading information, core company information, and a list of its key executives and their positions. The document also addresses frequently asked questions regarding the …
Short interest in Texas Ventures Acquisition III Corp (NASDAQ:TVA) significantly increased by 1,474.8% in July, reaching 59,891 shares, though its short-interest ratio remains low at 1.2 days. The company, a SPAC, has a consensus "Sell" rating from analysts, following downgrades. Despite the surge in …
DLD Asset Management LP significantly increased its stake in Texas Ventures Acquisition III Corp (NASDAQ:TVA) by 106.9% in the first quarter, bringing its total holdings to 197,072 shares valued at approximately $2.05 million. Other institutional investors like Harraden Circle Investments LLC also boosted their …
Tvardi Therapeutics (TVRD) is launching an at-the-market equity program to sell up to $9.7 million of common stock through JonesTrading. The proceeds are intended for general corporate purposes, including clinical trials, research and development, and potential in-licensing or acquisitions. This offering could result in …
Cara Therapeutics discussed its Q1 2022 financial results and commercial launch progress for KORSUVA injection in the U.S., highlighting initial positive reception and ordering by dialysis clinics. The company also announced the European approval of Kapruvia, triggering a $15 million milestone payment, and provided …
Search by ticker symbol or company name and select a result to open its chart.